Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 2/20 | 0.46 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.46 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.46 |
| ▸ | PRKCI | P41743 | 1/20 | 0.45 |
| ▸ | PRF1 | P14222 | 1/20 | 0.44 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | PDE2A | O00408 | 2/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CCND1 | P24385 | 1/20 | 0.43 |
| ▸ | CCNC | P24863 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | CDK7 | P50613 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4581864 | 0.78 | RAB9A (0.51) | DYRK1AFYNLRRK2NPC1RAB9A | |
| SCHEMBL15730523 | 0.78 | MKNK1 (0.70) | PARP1DYRK1AFYNBAZ2BBAZ2A | |
| SCHEMBL27668122 | 0.76 | PARP1 (0.59) | PARP1DYRK1AFYNBAZ2BBAZ2A | |
| SCHEMBL10282887 | 0.75 | FYN (0.51) | PARP1DYRK1AFYNBAZ2BBAZ2A | |
| SCHEMBL4581861 | 0.75 | NOS3 (0.41) | NPC1RAB9AGABRPGABRDGABRA1 | |
| SCHEMBL4504821 | 0.75 | MTOR (0.57) | NPC1RAB9A | |
| SCHEMBL15928353 | 0.75 | FYN (0.45) | FYNPRKCIMAP2K4LRRK2CDK8 | |
| SCHEMBL15928351 | 0.75 | CA1 (0.51) | PRF1LRRK2BRD4 | |
| SCHEMBL15928349 | 0.74 | ALOX5AP (0.43) | MKNK1MKNK2GABRPGABRDGABRA1 | |
| SCHEMBL3701695 | 0.74 | PARP1 (0.51) | PARP1DYRK1AFYNBAZ2BBAZ2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2943481-B1 | (HETERO)ARYLACETAMIDE DERIVATIVES AS ANTIRETROVIRAL AGENTS | GILEAD SCIENCES INC (US) | 2018-05-02 | — | — | EP | disclosed |
| US-9050344-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20140221346-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221346-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, G6PD | PARP1 2578/4885DYRK1A 4884/4885FYN 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.